Literature DB >> 22780971

[Generation of a herpes simplex virus-permissive mouse melanoma cell line B16RHSV].

Xiu-fen Zhuang1, Ai-ping Zhou, Gui-lan Shi, Xiang-ping Han, Jie Li, Yu Zhang, You-hui Zhang, Shu-ren Zhang, Bin-lei Liu.   

Abstract

OBJECTIVE: To generate an oncolytic herpes simplex virus (oHSV) permissive mouse melanoma cell line B16RHSV, preserving the tumorigenic ability in syngeneic mice.
METHODS: The herpes simplex virus entry mediator (HVEM) gene was amplified by PCR from human melanoma cell line A375, and cloned into pGEM-T Easy vector for sequencing. The HVEM gene was then cloned into pcDNA3 vector to generate pcDNA3-HVEM for transfection of mouse melanoma cell line B16-F10 cells. After that, the putative transfected cells were selected in full growth medium containing G418. The HVEM-expressing cells were isolated by immunomagnetic bead separation. The mouse melanoma cell line expressing oHSV receptor-HVEM, designated as B16RHSV, was generated. The permissibility of B16RHSV cells to oHSV infection was examined with green fluorescence protein (GFP)-expressing oHSV (oHSVGFP). To investigate the tumorigenic ability of both cells in vivo, 2×10(5) cells in 100 µl were subcutaneously inoculated into the right flanks of C57/BL mice.
RESULTS: In vitro, the B16RHSV mouse melanoma cells were shown by fluorescence microscopy capable of being infected by oHSVGFP. In vivo, the B16RHSV cells, like their wild type counterpart, grew to form melanoma in syngeneic mice.
CONCLUSION: A herpes simplex virus-permissive mouse melanoma cell line was established. Its tumorigenicity remained unchanged.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22780971     DOI: 10.3760/cma.j.issn.0253-3766.2012.03.006

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  3 in total

1.  A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy.

Authors:  Han Hu; Siqi Zhang; Linkang Cai; Haixiao Duan; Yuying Li; Junhan Yang; Yang Wang; Biao Liu; Shuang Dong; Zhizheng Fang; Binlei Liu
Journal:  Virol J       Date:  2022-04-22       Impact factor: 5.913

2.  A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.

Authors:  Qian Zhao; Wen Zhang; Zhifeng Ning; Xiufen Zhuang; Haizhen Lu; Jing Liang; Jie Li; Yu Zhang; Ying Dong; Youhui Zhang; Shuren Zhang; Shangmei Liu; Binlei Liu
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

3.  Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1.

Authors:  Yujie Zhu; Xiao Hu; Lin Feng; Zhenrong Yang; Lulin Zhou; Xinchun Duan; Shujun Cheng; Wen Zhang; Binlei Liu; Kaitai Zhang
Journal:  Mol Ther Oncolytics       Date:  2019-10-23       Impact factor: 7.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.